{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:35:38Z","timestamp":1769049338102,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00105-024-05352-5","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:02:34Z","timestamp":1716476554000},"page":"459-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alopezie durch Chemotherapeutika, Hedgehog-Inhibitoren, zielgerichtete Antik\u00f6rpertherapien und Immuncheckpointinhibitoren","Alopecia due to chemotherapeutics, hedgehog inhibitors, targeted antibody therapies and immune checkpoint inhibitors"],"prefix":"10.1007","volume":"75","author":[{"given":"M. M.","family":"Sachse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"341","key":"5352_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM199908123410706","volume":"1999","author":"R Paus","year":"1999","unstructured":"Paus\u00a0R, Cotsarelis\u00a0G (1999) The biology of hair follicles. N\u00a0Engl J Med 341(7):491\u2013497","journal-title":"N Engl J Med"},{"key":"5352_CR2","unstructured":"Wolff et\u00a0al (2016) Diagnostik und Therapie von Haar- und Kopfhauterkrankungen. Dtsch Arztebl Int 113: 377\u201386"},{"key":"5352_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2133.1996.tb07839.x","volume":"134","author":"M Courtois","year":"1996","unstructured":"Courtois\u00a0M et\u00a0al (1996) Periodicity in the growth and shedding of hair. Br J Dermatol 134:47\u201354","journal-title":"Br J Dermatol"},{"key":"5352_CR4","first-page":"14","volume":"17","author":"IS Haslam","year":"2019","unstructured":"Haslam\u00a0IS, Smart\u00a0E (2019) Chemotherapy-Induced Hair Loss: The Use of Biomarkers for Predicting Alopecic Severity and Treatment Efficacy. Biomark Insights 17:14","journal-title":"Biomark Insights"},{"key":"5352_CR5","series-title":"Palliat","first-page":"281","volume-title":"Chemotherapy-induced alopecia. Curr Opin Suppor","author":"RM Trueb","year":"2010","unstructured":"Trueb\u00a0RM (2010) Chemotherapy-induced alopecia. Curr Opin Suppor. Palliat, Bd. 4, S\u00a0281\u2013284"},{"issue":"2","key":"5352_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1101\/gad.1258705","volume":"19","author":"ME Hutchin","year":"2005","unstructured":"Hutchin\u00a0ME et\u00a0al (2005) Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev 19(2):214\u2013223","journal-title":"Genes Dev"},{"issue":"6","key":"5352_CR7","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/bjd.15738","volume":"177","author":"C Dessinioti","year":"2017","unstructured":"Dessinioti\u00a0C, Antoniou\u00a0C, Stratigos\u00a0AJ (2017) From basal cell carcinoma morphogenesis to the alopecia induced by hedgehog inhibitors: connecting the dots. Br J Dermatol 177(6):1485\u20131494","journal-title":"Br J Dermatol"},{"issue":"4","key":"5352_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jaad.2015.01.011","volume":"72","author":"BM Piraccini","year":"2015","unstructured":"Piraccini\u00a0BM et\u00a0al (2015) RASopathic alopecia: hair changes associated with vemurafenib therapy. J\u00a0Am Acad Dermatol 72(4):738\u2013741","journal-title":"J Am Acad Dermatol"},{"key":"5352_CR9","doi-asserted-by":"crossref","unstructured":"Lacouture M, Sibaud (2018) Toxic side effects of targeted therapies and immunotherapies affecting theskin, oral mucosa, hair, and nails. Am J Clin Dermatol 19(suppl 1):31\u201339","DOI":"10.1007\/s40257-018-0384-3"},{"key":"5352_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/bjd.15237","volume":"176","author":"A Zarbo","year":"2017","unstructured":"Zarbo\u00a0A et\u00a0al (2017) Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 176:1649\u20131652","journal-title":"Br J Dermatol"},{"key":"5352_CR11","doi-asserted-by":"crossref","unstructured":"Belum VR et\u00a0al (2015) Alopecia in patients treated with molecularly targeted anticancer therapies Ann Oncol. 26(12):2496\u2013502","DOI":"10.1093\/annonc\/mdv390"},{"key":"5352_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/jjco\/hyg075","volume":"33","author":"K Sato","year":"2003","unstructured":"Sato\u00a0K et\u00a0al (2003) Multicenter phase ii trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (sbccsg-01). Jpn J Clin Oncol 33:371\u2013376","journal-title":"Jpn J Clin Oncol"},{"key":"5352_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.1995.13.2.314","volume":"13","author":"B Chevallier","year":"1995","unstructured":"Chevallier\u00a0B et\u00a0al (1995) Docetaxel is a\u00a0major cytotoxic drug for the treatment of advanced breast cancer: a\u00a0phase ii trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J\u00a0Clin Oncol 13:314\u2013322","journal-title":"J Clin Oncol"},{"key":"5352_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jaad.2018.04.046","volume":"79","author":"AK Rzepecki","year":"2021","unstructured":"Rzepecki\u00a0AK et\u00a0al (2021) Cutaneous toxicity as a\u00a0predictive biomarker for clinical outcome in patients receiving anticancer therapy. J\u00a0Am Acad Dermatol 79:545\u2013555","journal-title":"J Am Acad Dermatol"},{"key":"5352_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/archderm.142.2.166","volume":"142","author":"SH Jaber","year":"2006","unstructured":"Jaber\u00a0SH et\u00a0al (2006) Skin reactions in a\u00a0subset of patients with stage\u00a0IV melanoma treated with anti-cytotoxic T\u2011lymphocyte antigen 4 monoclonal antibody as a\u00a0single agent. Arch Dermatol 142:166\u2013172","journal-title":"Arch Dermatol"},{"key":"5352_CR16","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian\u00a0SL et\u00a0al (2012) Safety, activity, and immune correlates of anti-PD\u20111 antibody in cancer. N\u00a0Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"5352_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann\u00a0L et\u00a0al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD\u20111 therapy. Eur J Cancer 60:190\u2013209","journal-title":"Eur J Cancer"},{"key":"5352_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/ejhpharm-2020-002347","volume":"28","author":"C Peng","year":"2021","unstructured":"Peng\u00a0C, Jie-Xin\u00a0L (2021) The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a\u00a0systematic review and meta-analysis. Eur J Hosp Pharm 28:182\u2013189","journal-title":"Eur J Hosp Pharm"},{"key":"5352_CR19","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Supportive Therapie bei onkologischen PatientInnen \u2013 Langversion 1.1, 2017, AWMF Registernummer: 032\/054OL, http:\/\/leitlinienprogrammonkologie.de\/Supportive-Therapie.95.0.html (Zugriff am 1. M\u00e4rz 2024)"},{"key":"5352_CR20","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","volume":"14","author":"R Paus","year":"2013","unstructured":"Paus\u00a0R et\u00a0al (2013) Pathobiology of chemotherapy-induced hair loss. Lancet Oncol 14:e50\u2013e59","journal-title":"Lancet Oncol"},{"key":"5352_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/bjd.12716","volume":"170","author":"V Kanti","year":"2014","unstructured":"Kanti\u00a0V et\u00a0al (2014) Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a\u00a0cohort study. Br J Dermatol 170:643\u2013650","journal-title":"Br J Dermatol"},{"issue":"7522","key":"5352_CR22","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bmj.331.7522.951","volume":"331","author":"N Hunt","year":"2005","unstructured":"Hunt\u00a0N, McHale\u00a0S (2005) The psychological impact of alopecia. BMJ 331(7522):951\u2013953","journal-title":"BMJ"},{"issue":"5","key":"5352_CR23","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler\u00a0AN et\u00a0al (2020) Immune checkpoint inhibitor-related dermatologic adverse events. J\u00a0Am Acad Dermatol 83(5):1255\u20131268","journal-title":"J Am Acad Dermatol"},{"key":"5352_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","volume":"28","author":"V Sibaud","year":"2016","unstructured":"Sibaud\u00a0V et\u00a0al (2016) Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28:254\u2013263","journal-title":"Curr Opin Oncol"},{"key":"5352_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud\u00a0V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19:345\u2013361","journal-title":"Am J Clin Dermatol"},{"key":"5352_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/EDBK_159514","volume":"35","author":"P Kluetz","year":"2016","unstructured":"Kluetz\u00a0P et\u00a0al (2016) Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 35:67\u201373","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"5352_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/annonc\/mdt476","volume":"25","author":"J Cho","year":"2014","unstructured":"Cho\u00a0J et\u00a0al (2014) Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients. Ann Oncol 25(2):346\u2013351","journal-title":"Ann Oncol"},{"key":"5352_CR28","doi-asserted-by":"publisher","first-page":"e2020074","DOI":"10.5826\/dpc.1003a74","volume":"10","author":"A Rossi","year":"2020","unstructured":"Rossi\u00a0A et\u00a0al (2020) Prevention and Treatment of Chemotherapy-Induced Alopecia. Dermatol Pract Concept 10:e2020074","journal-title":"Dermatol Pract Concept"},{"key":"5352_CR29","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.3390\/curroncol30040275","volume":"30","author":"TC Wikramanayake","year":"2023","unstructured":"Wikramanayake\u00a0TC et\u00a0al (2023) Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming? Curr Oncol 30:3609\u20133626","journal-title":"Curr Oncol"},{"issue":"16","key":"5352_CR30","first-page":"5090","volume":"25","author":"XF Shen","year":"2021","unstructured":"Shen\u00a0XF, Ru\u00a0LX, Yao\u00a0XB (2021) Efficacy of scalp cooling for prevention of chemotherapy induced alopecia: a\u00a0systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 25(16):5090\u20135103","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"5352_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10549-019-05169-0","volume":"175","author":"DH Marks","year":"2019","unstructured":"Marks\u00a0DH et\u00a0al (2019) The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a\u00a0systematic review. Breast Cancer Res Treat 175(2):267\u2013276","journal-title":"Breast Cancer Res Treat"},{"key":"5352_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13395","volume-title":"Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary","author":"J Chan","year":"2021","unstructured":"Chan\u00a0J et\u00a0al (2021) Permanent hair loss associated with taxane chemotherapy use in breast cancer: A\u00a0retrospective survey at two tertiary UK\u00a0cancer centres. Eur J Cancer Care (Engl) 30(3):e13395. https:\/\/doi.org\/10.1111\/ecc.13395"},{"key":"5352_CR33","doi-asserted-by":"crossref","unstructured":"Purba Ts (2019) CDK4\/6 inhibition mitigates stem cell damage in a\u00a0novel model for taxane-induced alopecia. EMBO Mol Med 11e11031","DOI":"10.15252\/emmm.201911031"},{"key":"5352_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/bjd.20745","volume":"186","author":"I Piccini","year":"2022","unstructured":"Piccini\u00a0I (2022) Peroxisome proliferator-activated receptor\u2011\u03b3 signalling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial-mesenchymal transition. Br J Dermatol 186:129\u2013141","journal-title":"Br J Dermatol"},{"issue":"9","key":"5352_CR35","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jid.2023.02.033","volume":"143","author":"J Cheret","year":"2023","unstructured":"Cheret\u00a0J et\u00a0al (2023) Low-Intensity Ultrasound as a\u00a0Potential Intervention Strategy to Protect Human Scalp Hair Follicles from Taxane-Induced Toxicity. J\u00a0Invest Dermatol 143(9):1809\u20131813.e2","journal-title":"J Invest Dermatol"},{"issue":"5","key":"5352_CR36","doi-asserted-by":"publisher","first-page":"E442","DOI":"10.1002\/ijc.29115","volume":"136","author":"H Shin","year":"2015","unstructured":"Shin\u00a0H et\u00a0al (2015) Efficacy of interventions for prevention of chemotherapy-induced alopecia: a\u00a0systematic review and meta-analysis. Int J Cancer 136(5):E442\u201354","journal-title":"Int J Cancer"},{"issue":"4","key":"5352_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00001813-199904000-00007","volume":"10","author":"M Hidalgo","year":"1999","unstructured":"Hidalgo\u00a0M et\u00a0al (1999) A phase\u00a0I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anticancer Drugs 10(4):393\u2013395","journal-title":"Anticancer Drugs"},{"key":"5352_CR38","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/pon.1637","volume":"19","author":"EL McGarvey","year":"2010","unstructured":"McGarvey\u00a0EL et\u00a0al (2010) An evaluation of a\u00a0computer-imaging program to prepare women for chemotherapy-related alopecia. Psychooncology 19:756\u2013766","journal-title":"Psychooncology"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05352-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T11:47:19Z","timestamp":1717501639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05352-5"}},"subtitle":["Pathogenese, Klinik, Diagnostik und Prophylaxe","Pathogenesis, clinical picture, diagnostics and prophylaxis"],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5352"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05352-5","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"10 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.M.\u00a0Sachse und K.C.\u00a0K\u00e4hler geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}